Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPhospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic
Expert Opinion on Investigational Drugs, 09/29/09
Suckling KE – Phase II results of the trials of two phospholipase A2 inhibitors which may be of value in the treatment of atherosclerosis and cardiovascular disease have been reported in the past year. Darapladib is an inhibitor of lipoprotein–associated phospholipase A2 and varespladib inhibits several forms of the secreted phospholipase A2s. Despite the apparent similarity of mechanism, which is also built into the compounds' names, the role of the two types of phospholipase in atherogenesis is very different.
Related Articles
Heat-shock protein 90: A novel autoantigen in human carotid atherosclerosis
Atherosclerosis, 11/12/09
Relevance Score: 91%
Microarray analysis of senescent vascular smooth muscle cells: A link to atherosclerosis and vascular calcification
Experimental Gerontology, 11/12/09
Relevance Score: 89%
Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering—lipoprotein changes and interactions: the SANDS study
Journal of Clinical Lipidology, 10/14/09
Relevance Score: 89%
Periodontal treatment influences risk markers for atherosclerosis in patients with severe periodontitis
Atherosclerosis, 10/09/09
Relevance Score: 89%
Liver X Receptors as potential therapeutic targets in atherosclerosis
Clinical and Investigative Medicine, 10/06/09
Relevance Score: 89%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Beta-Adrenergic Antagonists in Hypertension: A Review of the Evidence
Annals of Pharmacotherapy, 11/25/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Sponsor
Article Search
Sponsor